Complete Consolidative Radiotherapy Improves Survival in Extensive-Stage Small Cell Lung Cancer

Clinical Summary:

• Design/Population: A retrospective cohort study compared outcomes with complete and incomplete consolidative radiotherapy in patients with extensive-stage small cell lung cancer, stratified by oligometastatic and polymetastatic disease.
• Key Outcomes: Complete consolidative radiotherapy was associated with improved overall and progression-free survival compared with incomplete radiotherapy. Oligometastatic status alone was not independently predictive of outcomes.
• Clinical Relevance: Delivering radiotherapy to all sites of residual disease may be more important than metastatic burden alone in improving outcomes for patients with extensive-stage small cell lung cancer. 

Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes among patients with extensive-stage small cell lung cancer (SCLC).

In this study, researchers collected data from 70 patients who underwent consolidative radiotherapy following first-line treatment with systemic therapy. Patients were classified by having received either complete (n = 28) or incomplete (n = 42) consolidative radiotherapy and further stratified as either oligometastatic (n = 36) or polymetastatic (n = 34). Key primary end points included overall survival (OS) and progression-free survival (PFS), adjusted by restricted mean survival time (RMST) analyses, accounting for clinical and treatment variables.

At a median follow-up of 38.2 months, adjusted analyses showed that complete consolidative radiotherapy was associated with an adjusted RMST gain in OS of 6.47 months (95% confidence interval [CI], 1.08 to 11.85; P = .0185)and a gain of 4.63 months in PFS (95% CI, 1.12 to 8.14; P = .0097) through 36 months compared with incomplete consolidative radiotherapy. 

Among patients with oligometastatic disease, complete consolidative radiotherapy was associated with an OS RMST gain of 7.90 months (95% CI, 1.75 to 14.05; P = .0118) through 36 months and a PFS RMST gain of 2.46 months (95% CI, 0.24 to 4.67; P = .0298) through 12 months. However, oligometastatic status alone was not independently associated with improved survival outcomes after adjustment for covariates.

“[Complete consolidative radiotherapy] was associated with improved OS and PFS compared with [incomplete consolidative radiotherapy]  in [extensive-stage] SCLC, whereas oligometastatic status alone was not independently associated with these outcomes,” concluded study authors. “These findings warrant prospective validation.”

Source:

Ninia JG, Verma N, Long JB, et al. Consolidative radiotherapy for extensive-stage small cell lung cancer: Outcomes based on completeness of consolidation and oligometastatic state. Clin Lung Cancer. Published online: March 25, 2026. doi:10.1016/j.cllc.2026.03.009